RSR13 ADMINISTERED TO PATIENTS RECEIVING CRANIAL RADIATION THERAPY

这项研究旨在评估肿瘤对RSR13的反应，RSR13是一种研究药物，在给予辐射时，可以增加血液中释放到组织中的氧气量。肿瘤缺氧会降低放射治疗的效果；因此，RSR13可能通过增加向肿瘤的氧气输送来提高放射治疗的有效性。RSR13的安全性也将被评估。RSR13在多形性胶质母细胞瘤中的有效性尚不清楚。放射治疗不是实验性的，是多形性胶质母细胞瘤的标准治疗方法。本研究中给予的RSR13将与标准放射治疗一起给予。本研究的主要目的是评估RSR13如何影响接受标准放射治疗的多形性胶质母细胞瘤患者的生存。我们还将评估每日重复静脉注射RSR13的安全性，该剂量可以与放射治疗一起给予。

This study is designed to evaluate how well tumors respond to RSR13, an investigational drug that increases the amount of oxygen released from blood into the tissues, when given with radiation. Lack of oxygen in a tumor can reduce the effectiveness of radiation therapy; therefore, RSR13 may improve the effectiveness of radiation therapy by increasing oxygen delivery to the tumor. The safety of RSR13 will also be evaluated. The effectiveness of RSR13 in glioblastoma multiforme is not known. Radiation therapy is not experimental and is the standard treatment for glioblastoma multiforme. The RSR13 given in this study will be given with standard radiation therapy treatments. The main objective of this study is to evaluate how RSR13 affects the survival of patients with glioblastoma multiforme treated with standard radiation therapy. We will also evaluate the safety of repetitive daily intravenous doses of RSR13 that can be given with radiation therapy.